Jazz Pharma in-licenses lung cancer candidate from PharmaMar

Jazz Pharmaceuticals (JAZZ +0.9%) inks an agreement with Spanish drug maker PharmaMar for exclusive U.S. rights to cancer med lurbinectedin, an inhibitor on oncogenic transcription (interferes with gene expression in cancer cells).

Under the terms of the deal, Jazz will pay PharmaMar $200M upfront, up to $250M in regulatory milestones, up to $550M in commercial milestones and tiered high teens-to-30% royalties on net sales. PharmaMar will be responsible for manufacturing and supply.

PharmaMar submitted a U.S. marketing application earlier this month seeking accelerated approval for relapsed small cell lung cancer, an Orphan Drug indication.

https://seekingalpha.com/news/3527440-jazz-pharma-in-licenses-lung-cancer-candidate-from-pharmamar